Compounded Wellness Peptides Under Scrutiny: tECRI and ISMP Safety Warning
Episode Summary
FDA’s 2026 regulatory shift on compounded peptides highlights major evidence gaps, manufacturing risks, and safety concerns, requiring clinicians to counsel patients and strengthen monitoring.